Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model

• Published in: Addictive behaviors 2015-02, Vol.41, p.20-28
• Main Authors: Northrup, Thomas F, Stotts, Angela L, Green, Charles, Potter, Jennifer S, Marino, Elise N, Walker, Robrina, Weiss, Roger D, Trivedi, Madhukar
• Format: Article
• Language: English
• Subjects: Addictive behaviors; Adult; Analgesics; Analgesics, Opioid - adverse effects; Buprenorphine; Buprenorphine - therapeutic use; Craving; Disease-Free Survival; Drug abuse; Drug use; Female; Humans; Latent class; Male; Narcotic Antagonists - therapeutic use; Opiate Substitution Treatment; Opioid; Opioid-Related Disorders - drug therapy; Outpatients - statistics & numerical data; Psychiatry; Recurrence; Relapse; Substance Withdrawal Syndrome - epidemiology; Treatment Outcome; Withdrawal
• ISSN: 0306-4603; 1873-6327
• DOI: 10.1016/j.addbeh.2014.09.021

Abstract Introduction Most patients relapse to opioids within one month of opioid agonist detoxification, making the antecedents and parallel processes of first use critical for investigation. Craving and withdrawal are often studied in relationship to opioid outcomes, and a novel analytic strategy applied to these two phenomena may indicate targeted intervention strategies. Methods Specifically, this secondary data analysis of the Prescription Opioid Addiction Treatment Study used a discrete-time mixture analysis with time-to-first opioid use (survival) simultaneously predicted by craving and withdrawal growth trajectories. This analysis characterized heterogeneity among prescription opioid-dependent individuals (N = 653) into latent classes (i.e., latent class analysis [LCA]) during and after buprenorphine/naloxone stabilization and taper. Results A 4-latent class solution was selected for overall model fit and clinical parsimony. In order of shortest to longest time-to-first use, the 4 classes were characterized as 1) high craving and withdrawal, 2) intermediate craving and withdrawal, 3) high initial craving with low craving and withdrawal trajectories and 4) a low initial craving with low craving and withdrawal trajectories. Odds ratio calculations showed statistically significant differences in time-to-first use across classes. Conclusions Generally, participants with lower baseline levels and greater decreases in craving and withdrawal during stabilization combined with slower craving and withdrawal rebound during buprenorphine taper remained opioid-free longer. This exploratory work expanded on the importance of monitoring craving and withdrawal during buprenorphine induction, stabilization, and taper. Future research may allow individually tailored and timely interventions to be developed to extend time-to-first opioid use.